Clinical Trial Update: Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating tivantinib for relapsed or relapsed and refractory multiple myeloma has completed with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• tivantinib (tivantinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Refractory Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2015-03-13